Industry Verticals »

All Categories

Insights »

About TMR »

Viral Vector & Plasmid DNA Manufacturing Market

Viral Vector & Plasmid DNA Manufacturing Market (Type: Lentivirus, Adenovirus Adeno-associated Virus (AAV), Plasmid DNA, and Others; Application: Gene Therapy, Vaccinology, and Others; Disease: Genetic Disorders, Cancer, Infectious Diseases, and Others; End-user: Biotech Companies and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Global Viral Vector & Plasmid DNA Manufacturing Market: Overview

  • This report analyzes the current scenario and future growth prospects of the global viral vector & plasmid DNA manufacturing market
  • The report provides an elaborate executive summary, which provides a snapshot of various segments of the global viral vector & plasmid DNA manufacturing market. It also provides information and data analysis of the global viral vector & plasmid DNA manufacturing market with respect to segments based on product, application, end-user, and region.
  • The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that impact the global viral vector & plasmid DNA manufacturing market
  • The report includes company profiles, which provide information about business strategies, product portfolios, and financials of players operating in the global viral vector & plasmid DNA manufacturing market and competition landscape of the market
  • The report on the global viral vector & plasmid DNA manufacturing market offers attractiveness analysis of different segments of the market across regions
  • The last section of the report comprises quantitative and qualitative analysis on market share/position of key players operating in the global viral vector & plasmid DNA manufacturing market. It analyzes key competitive strategies adopted by major market players, thereby presenting a thorough understanding of the competition scenario in the global viral vector & plasmid DNA manufacturing market.
global viral vector plasmid dna manufacturing market revenue share by region

Global Viral Vector & Plasmid DNA Manufacturing Market: Key Segments

  • In terms of type, the global viral vector & plasmid DNA manufacturing market can be classified into lentivirus, adenovirus, adeno-associated virus (AAV), plasmid DNA, and others. The plasmid DNA segment accounted for major market share in 2018.
  • Increase in awareness about gene therapy and technological advancements in the production of plasmid DNA are projected to fuel the growth of the plasmid DNA segment during the forecast period
  • Based on application, the global viral vector & plasmid DNA manufacturing market has been segmented into gene therapy, vaccinology, and others
  • The gene therapy segment accounted for the largest market share in 2018. Growth of the segment can be attributed to rich product pipeline and increase in the number of companies manufacturing vector-based products for gene therapies.
  • In terms of disease, the global viral vector & plasmid DNA manufacturing market has been categorized into genetic disorders, cancer, infectious diseases, and others
  • The cancer segment accounted for the largest market share in 2018. Growth of the segment can be attributed to high prevalence of cancer and increased acceptance of gene therapy for the treatment of cancer.
  • Based on end-user, the global viral vector & plasmid DNA manufacturing market has been bifurcated into biotech companies and research institutes. The biotech companies segment accounted for major market share in 2018 and the trend is projected to continue in the near future. The biotech companies segment is anticipated to witness significant growth, owing to increase in investment by biotech companies in vector-based technologies and high demand for new therapies.
  • Market size and forecast for each of the segments of the global viral vector & plasmid DNA manufacturing market have been provided for the period from 2017 to 2027. The CAGRs of the segments of the global viral vector & plasmid DNA manufacturing market have also been provided for the period from 2019 to 2027, considering 2018 as the base year.

Global Viral Vector & Plasmid DNA Manufacturing Market: Regional Outlook

  • In terms of region, the global viral vector & plasmid DNA manufacturing market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). Each region of the global viral vector & plasmid DNA manufacturing market has been divided into countries/sub-regions.
  • The report provides size and forecast of the global viral vector & plasmid DNA manufacturing market in each region and country/sub-region for the period from 2017 to 2027. The CAGR for the market in each of these regions and countries/sub-regions has also been provided for the period from 2019 to 2027. The study also covers the market competition scenario in these regions. 

Companies Covered in Report on Global Viral Vector & Plasmid DNA Manufacturing Market

  • Key players in the global viral vector & plasmid DNA manufacturing market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
  • Major companies profiled in the global viral vector & plasmid DNA manufacturing market report are
    • CobraBiologics
    • Novasep, Inc.
    • Cell and Gene Therapy Catapult
    • Kaneka Eurogentec S.A.
    • FUJIFILM Diosynth Biotechnologies, Inc.
    • Spark Therapeutics, Inc.
    • Merck KGaA
    • uniQure N.V.
    • Lonza

Frequently Asked Questions

What is the total market worth of viral vector & plasmid DNA manufacturing market?

Viral vector & plasmid DNA manufacturing market to reach US$ 2.3 Bn by 2027

What is the anticipated CAGR of the viral vector & plasmid DNA manufacturing market in the forecast period?

Viral vector & plasmid DNA manufacturing market is projected to expand at a CAGR of 23.3% from 2019 to 2027

What are the key driving factors for the growth of the viral vector & plasmid DNA manufacturing market?

Viral vector & plasmid DNA manufacturing market is driven by increase in awareness about viral vector-based treatments

Which is the rising prominent segment in the viral vector & plasmid DNA manufacturing market?

The plasmid DNA segment dominated the global viral vector & plasmid DNA manufacturing market and the trend is expected to continue during the forecast period

Who are the key players in the viral vector & plasmid DNA manufacturing market?

Key players in the global viral vector & plasmid DNA manufacturing market include CobraBiologics, Novasep Inc., Cell and Gene Therapy Catapult, Kaneka Eurogentec S.A., FUJIFILM Diosynth Biotechnologies, Inc.

    1. Preface 

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Viral Vector & Plasmid DNA Manufacturing Market

    4. Market Overview

        4.1. Introduction

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast, 2017–2027

    5. Market Outlook

        5.1. Evolution of Gene Therapy

        5.2. Key Mergers & Acquisitions

        5.3. Pipeline Analysis

        5.4. List of Manufacturers, by Location of Manufacturing Facility & Type of Vector Production 

    6. Global Viral Vector & Plasmid DNA Manufacturing Market Value and Forecast, by Type

        6.1. Introduction 

        6.2. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027

            6.2.1. Lentivirus

            6.2.2. Adenovirus 

            6.2.3. Adeno-associated Virus (AAV)

            6.2.4. Plasmid DNA

            6.2.5. Others 

        6.3. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type

    7. Global Viral Vector & Plasmid DNA Manufacturing Market Value and Forecast, by Application

        7.1. Introduction 

        7.2. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027

            7.2.1. Gene Therapy

            7.2.2. Vaccinology

            7.2.3. Others 

        7.3. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application

    8. Global Viral Vector & Plasmid DNA Manufacturing Market Value and Forecast, by Disease

        8.1. Introduction 

        8.2. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027

            8.2.1. Genetic Disorders

            8.2.2. Cancer

            8.2.3. Infectious Diseases

            8.2.4. Others

        8.3. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease

    9. Global Viral Vector & Plasmid DNA Manufacturing Market Value and Forecast, by End-user

        9.1. Introduction 

        9.2. Global Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027

            9.2.1. Biotech Companies

            9.2.2. Research Institutes

        9.3. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user

    10. Global Viral Vector & Plasmid DNA Manufacturing Market Value and Forecast, by Region

        10.1. Introduction 

        10.2  Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Region, 2017–2027

            10.1.1. North America

            10.1.2. Europe

            10.1.3. Asia Pacific

            10.1.4. Latin America

            10.1.5. Middle East & Africa

        10.3. Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Region

    11. North America Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast 

        11.1. Introduction

        11.2. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027

            11.2.1. Lentivirus

            11.2.2. Adenovirus 

            11.2.3. Adeno-associated Virus (AAV)

            11.2.4. Plasmid DNA

            11.2.5. Others

        11.3. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027

            11.3.1. Gene Therapy

            11.3.2. Vaccinology

            11.3.3. Others

        11.4. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027

            11.4.1. Genetic Disorders

            11.4.2. Cancer

            11.4.3. Infectious Diseases

            11.4.4. Others

        11.5. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027

            11.5.1. Biotech Companies

            11.5.2. Research Institutes

        11.6. North America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country, 2017–2027

            11.6.1. U.S.

            11.6.2. Canada

        11.7. North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis

            11.7.1. By Type

            11.7.2. By Application

            11.7.3. By Disease

            11.7.4. By End-user

            11.7.5. By Country

    12. Europe Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast 

        12.1. Introduction

        12.2. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027

            12.2.1. Lentivirus

            12.2.2. Adenovirus 

            12.2.3. Adeno-associated Virus (AAV)

            12.2.4. Plasmid DNA

            12.2.5. Others

        12.3. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027

            12.3.1. Gene Therapy

            12.3.2. Vaccinology

            12.3.3. Others

        12.4. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027

            12.4.1. Genetic Disorders

            12.4.2. Cancer

            12.4.3. Infectious Diseases

            12.4.4. Others

        12.5. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027

            12.5.1. Biotech Companies

            12.5.2. Research Institutes

        12.6. Europe Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017–2027

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy 

            12.6.6. Rest of Europe

        12.7. Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis

            12.7.1. By Type

            12.7.2. By Application

            12.7.3. By Disease

            12.7.4. By End-user

            12.7.5. By Country/Sub-region

    13. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast 

        13.1. Introduction

        13.2. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027

            13.2.1. Lentivirus

            13.2.2. Adenovirus 

            13.2.3. Adeno-associated Virus (AAV)

            13.2.4. Plasmid DNA

            13.2.5. Others

        13.3. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027

            13.3.1. Gene Therapy

            13.3.2. Vaccinology

            13.3.3. Others

        13.4. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027

            13.4.1. Genetic Disorders

            13.4.2. Cancer

            13.4.3. Infectious Diseases

            13.4.4. Others

        13.5. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027

            13.5.1. Biotech Companies

            13.5.2. Research Institutes

        13.6. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017–2027

            13.6.1. Japan

            13.6.2. China

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis

            13.7.1. By Type

            13.7.2. By Application

            13.7.3. By Disease

            13.7.4. By End-user

            13.7.5. By Country/Sub-region

    14. Latin America Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast 

        14.1. Introduction

        14.2. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027

            14.2.1. Lentivirus

            14.2.2. Adenovirus 

            14.2.3. Adeno-associated Virus (AAV)

            14.2.4. Plasmid DNA

            14.2.5. Others

        14.3. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027

            14.3.1. Gene Therapy

            14.3.2. Vaccinology

            14.3.3. Others

        14.4. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027

            14.4.1. Genetic Disorders

            14.4.2. Cancer

            14.4.3. Infectious Diseases

            14.4.4. Others

        14.5. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027

            14.5.1. Biotech Companies

            14.5.2. Research Institutes

        14.6. Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017–2027

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis

            14.7.1. By Type

            14.7.2. By Application

            14.7.3. By Disease

            14.7.4. By End-user

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Analysis and Forecast 

        15.1. Introduction

        15.2. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Type, 2017–2027

            15.2.1. Lentivirus

            15.2.2. Adenovirus 

            15.2.3. Adeno-associated Virus (AAV)

            15.2.4. Plasmid DNA

            15.2.5. Others

        15.3. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Application, 2017–2027

            15.3.1. Gene Therapy

            15.3.2. Vaccinology

            15.3.3. Others

        15.4. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Disease, 2017–2027

            15.4.1. Genetic Disorders

            15.4.2. Cancer

            15.4.3. Infectious Diseases

            15.4.4. Others

        15.5. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by End-user, 2017–2027

            15.5.1. Biotech Companies

            15.5.2. Research Institutes

        15.6. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Forecast, by Country/Sub-region, 2017–2027

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness Analysis

            15.7.1. By Type

            15.7.2. By Application

            15.7.3. By Disease

            15.7.4. By End-user

            15.7.5. By Country/Sub-region

    16. Competitive Landscape

        16.1.  Market Player -- Competition Matrix (By Tier and Size of companies)

        16.2.  Company Profiles

            16.2.1. Lonza

                16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.1.2. Product Portfolio

                16.2.1.3. SWOT Analysis

                16.2.1.4. Financial Overview

                16.2.1.5. Strategic Overview

            16.2.2. Catapult 

                16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.2.2. Product Portfolio

                16.2.2.3. SWOT Analysis

                16.2.2.4. Financial Overview

                16.2.2.5. Strategic Overview

            16.2.3. uniQure N.V.

                16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.3.2. Product Portfolio

                16.2.3.3. SWOT Analysis

                16.2.3.4. Financial Overview

                16.2.3.5. Strategic Overview

            16.2.4. FUJIFILM Diosynth Biotechnologies

                16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.4.2. Product Portfolio

                16.2.4.3. SWOT Analysis

                16.2.4.4. Financial Overview

                16.2.4.5. Strategic Overview

            16.2.5. Kaneka Eurogentec S.A.

                16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.5.2. Product Portfolio

                16.2.5.3. SWOT Analysis

                16.2.5.4. Financial Overview

                16.2.5.5. Strategic Overview

            16.2.6. Oxford Biomedica

                16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.6.2. Product Portfolio

                16.2.6.3. SWOT Analysis

                16.2.6.4. Financial Overview

                16.2.6.5. Strategic Overview

            16.2.7. Spark Therapeutics, Inc.

                16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.7.2. Product Portfolio

                16.2.7.3. SWOT Analysis

                16.2.7.4. Financial Overview

                16.2.7.5. Strategic Overview

            16.2.8. Cobrabiologics

                16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.8.2. Product Portfolio

                16.2.8.3. SWOT Analysis

                16.2.8.4. Financial Overview

                16.2.8.5. Strategic Overview

            16.2.9. Merck KGaA

                16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.2.9.2. Product Portfolio

                16.2.9.3. SWOT Analysis

                16.2.9.4. Financial Overview

                16.2.9.5. Strategic Overview

    List of Tables

    Table 01: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027

    Table 02: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027

    Table 03: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027

    Table 04: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027

    Table 05: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Region, 2017?2027

    Table 06: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country, 2017?2027

    Table 07: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027

    Table 08: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027

    Table 09: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027

    Table 10: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027

    Table 11: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 12: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027

    Table 13: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027

    Table 14: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027

    Table 15: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027

    Table 16: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 17: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027

    Table 18: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027

    Table 19: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027

    Table 20: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027

    Table 21: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 22: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027

    Table 23: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027

    Table 24: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027

    Table 25: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027

    Table 26: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 27: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2027

    Table 28: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Application, 2017?2027

    Table 29: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by Disease, 2017?2027

    Table 30: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017?2027

    List of Figures

    Figure 01: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027

    Figure 02: Global Viral Vector & Plasmid DNA Manufacturing Market Value, by Type, 2018(A) 

    Figure 03: Global Viral Vector & Plasmid DNA Manufacturing Market Snapshot

    Figure 04: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type

    Figure 05: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application

    Figure 06: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease

    Figure 07: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user

    Figure 08: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017?2027

    Figure 09: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018

    Figure 10: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018

    Figure 11: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Region, 2018

    Figure 12: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027

    Figure 13: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027

    Figure 14: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Lentivirus, 2017?2027

    Figure 15: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Adenovirus, 2017?2027

    Figure 16: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Adeno-associated Virus (AAV), 2017?2027

    Figure 17: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Plasmid DNA, 2017?2027

    Figure 18: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017?2027

    Figure 19: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027

    Figure 20: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027

    Figure 21: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Gene Therapy, 2017?2027

    Figure 22: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Vaccinology, 2017?2027

    Figure 23: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017?2027

    Figure 24: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027

    Figure 25: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027

    Figure 26: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Genetic Disorders, 2017?2027

    Figure 27: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cancer, 2017?2027

    Figure 28: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Infectious Diseases, 2017?2027

    Figure 29: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017?2027

    Figure 30: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027

    Figure 31: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027

    Figure 32: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biotech Companies, 2017?2027

    Figure 33: Global Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Research Institutes, 2017?2027

    Figure 34: Global Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Region, for 2018 and 2027 

    Figure 35: Global Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Region, 2019–2027

    Figure 36: North America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027

    Figure 37: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country, 2019–2027

    Figure 38: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country, 2018 and 2027

    Figure 39: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027

    Figure 40: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027

    Figure 41: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027

    Figure 42: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027

    Figure 43: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027

    Figure 44: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027

    Figure 45: North America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027

    Figure 46: North America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027

    Figure 47: Europe Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027

    Figure 48: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share (%), by Country/Sub-region, 2018 and 2027

    Figure 49: Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 50: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027

    Figure 51: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027

    Figure 52: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027

    Figure 53: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027

    Figure 54: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027

    Figure 55: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027

    Figure 56: Europe Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027

    Figure 57: Europe Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027

    Figure 58: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027

    Figure 59: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 60: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country/Sub-region, for 2018 and 2027

    Figure 61: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027

    Figure 62: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027

    Figure 63: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027

    Figure 64: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027

    Figure 65: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027

    Figure 66: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027

    Figure 67: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027

    Figure 68: Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027

    Figure 69: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027

    Figure 70: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 71: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country/Sub-region, 2018 and 2027

    Figure 72: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027

    Figure 73: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027

    Figure 74: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027

    Figure 75: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027

    Figure 76: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027

    Figure 77: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027

    Figure 78: Latin America Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027

    Figure 79: Latin America Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027

    Figure 80: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017?2027

    Figure 81: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Country/Sub-Region, 2019–2027

    Figure 82: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Country/Sub-Region, 2018 and 2027

    Figure 83: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Type, 2019–2027

    Figure 84: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Type, 2018 and 2027

    Figure 85: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Application, 2019–2027

    Figure 86: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Application, 2018 and 2027

    Figure 87: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by Disease, 2019–2027

    Figure 88: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by Disease, 2018 and 2027

    Figure 89: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Attractiveness, by End-user, 2019–2027

    Figure 90: Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Value Share, by End-user, 2018 and 2027

Copyright © Transparency Market Research, Inc. All Rights reserved

Viral Vector & Plasmid DNA Manufacturing Market

Schedule a Call